Selective TYK2 Pseudokinase Inhibitors for Reduced JAK Off-Target Effects
Solution Overview
Problem
Existing TYK2 inhibitors lack selectivity over other JAK kinases, particularly JAK2, leading to potential side effects and off-target effects in disease treatment.
Innovation Solution
Development of compounds that selectively inhibit the pseudokinase domain of TYK2, offering allosteric modulation and non-competitive inhibition, thereby reducing off-target effects and enhancing therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing TYK2 inhibitors are used, then TYK2 activity is inhibited, but selectivity over other JAK kinases is poor leading to off-target effects
Solution Approach 1:
The patent applies local quality by designing compounds that specifically target the unique structural features of the TYK2 pseudokinase domain (JH2) rather than the conserved catalytic domains shared across all JAK kinases. The compounds contain specific substituents and molecular features that interact with TYK2-specific residues in the JH2 domain, providing localized selectivity. This enables inhibition of TYK2 while sparing other JAK kinases (JAK1, JAK2, JAK3), thereby reducing off-target effects and improving therapeutic safety.
Solution Approach 2:
The patent segments the JAK kinase family by exploiting the distinct functional domains within TYK2, particularly the pseudokinase JH2 domain which has unique structural characteristics compared to other JAKs. By designing inhibitors that specifically bind to this segmented region (JH2) rather than the common catalytic domain, the compounds achieve selectivity. The segmentation approach allows differentiation between TYK2 and other JAK kinases based on their domain architecture, enabling targeted inhibition.
2Adaptability or versatility
If broad JAK inhibition is achieved, then multiple cytokine pathways are blocked, but side effects increase due to lack of selectivity
Solution Approach 1:
The compounds exhibit local quality by targeting the specific JH2 pseudokinase domain of TYK2 with unique structural features that do not cross-react with other JAK kinases. This localized targeting approach allows selective modulation of TYK2-mediated cytokine pathways (such as IL-12, IL-23, and type I interferon pathways) while preserving other JAK-dependent immune functions, thereby achieving pathway coverage without proportional increase in side effects.
Solution Approach 2:
The patent employs an intermediary approach by utilizing the JH2 pseudokinase domain as a unique binding site that mediates selective inhibition. The JH2 domain serves as an intermediary structure that the compounds exploit to achieve specificity - it is a necessary component of TYK2 function but has distinct structural features absent in other JAKs. By targeting this intermediary element, the compounds can modulate TYK2 activity without broadly affecting the entire JAK family, thus reducing harmful side effects.
Data Source
AI summary
Described herein are compounds that are TYK2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of TYK2 activity.